Investigational Drug Information for Telotristat ethyl
✉ Email this page to a colleague
What is the drug development status for Telotristat ethyl?
Telotristat ethyl is an investigational drug.
There have been 9 clinical trials for Telotristat ethyl.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.
The most common disease conditions in clinical trials are Neuroendocrine Tumors, Carcinoid Tumor, and Serotonin Syndrome. The leading clinical trial sponsors are Lexicon Pharmaceuticals, TerSera Therapeutics LLC, and M.D. Anderson Cancer Center.
There are thirteen US patents protecting this investigational drug and one hundred and twenty-three international patents.
Summary for Telotristat ethyl
| US Patents | 13 |
| International Patents | 123 |
| US Patent Applications | 68 |
| WIPO Patent Applications | 25 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2020-04-01) |
| Vendors | 42 |
Recent Clinical Trials for Telotristat ethyl
| Title | Sponsor | Phase |
|---|---|---|
| Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor | M.D. Anderson Cancer Center | Phase 3 |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl | TerSera Therapeutics LLC | Phase 2 |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl | Big Ten Cancer Research Consortium | Phase 2 |
Clinical Trial Summary for Telotristat ethyl
Top disease conditions for Telotristat ethyl
Top clinical trial sponsors for Telotristat ethyl
US Patents for Telotristat ethyl
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Telotristat ethyl | ⤷ Subscribe | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (Allschwil, CH) | ⤷ Subscribe |
| Telotristat ethyl | ⤷ Subscribe | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (Berlin, DE) FORSCHUNGSVERBUND BERLIN E.V. (Berlin, DE) | ⤷ Subscribe |
| Telotristat ethyl | ⤷ Subscribe | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Lexicon Pharmaceuticals, Inc. (The Woodlands, TX) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Telotristat ethyl
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Telotristat ethyl | Canada | CA2927121 | 2033-11-19 | ⤷ Subscribe |
| Telotristat ethyl | China | CN105745211 | 2033-11-19 | ⤷ Subscribe |
| Telotristat ethyl | European Patent Office | EP3071567 | 2033-11-19 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
